To the full analysis
AbbVie stock: growth
ABBVAbbVie reported $61.16B in revenue for fiscal 2025, up 8.6% on the prior year, up 6% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
9.5%
per year from 2009 to 2025, per share 8.9%
Earnings (Annual rate)
−0.6%
per year from 2009 to 2025, per share −1.2%
Free cash flow (Annual rate)
8.2%
per year from 2009 to 2025, per share 7.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2009 | |
|---|---|---|---|
| Revenue | 6.0% | 10.3% | 9.5% |
| Revenue per share | 4.6% | 9.4% | 8.9% |
| Earnings | −1.7% | −1.9% | −0.6% |
| Earnings per share | −2.8% | −2.8% | −1.2% |
| Free cash flow | 1.2% | 9.8% | 8.2% |
| Free cash flow per share | −0.1% | 8.8% | 7.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2009 | $14.21B | $4.64B | $5.05B |
| 2010 | $15.64B | $4.18B | $4.53B |
| 2011 | $17.44B | $3.43B | $5.89B |
| 2012 | $18.38B | $5.28B | $6.01B |
| 2013 | $18.79B | $4.13B | $5.78B |
| 2014 | $19.96B | $1.77B | $2.94B |
| 2015 | $22.86B | $5.14B | $7B |
| 2016 | $25.64B | $5.95B | $6.56B |
| 2017 | $28.22B | $5.31B | $9.43B |
| 2018 | $32.75B | $5.69B | $12.79B |
| 2019 | $33.27B | $7.88B | $12.77B |
| 2020 | $45.8B | $4.62B | $16.79B |
| 2021 | $56.2B | $11.54B | $21.99B |
| 2022 | $58.05B | $11.84B | $24.25B |
| 2023 | $54.32B | $4.86B | $22.06B |
| 2024 | $56.33B | $4.28B | $17.83B |
| 2025 | $61.16B | $4.23B | $17.82B |
Revenue by segment
How AbbVie Inc. makes its money and how that has shifted. Names are as the company reports them.
- Skyrizi29%
- Rinvoq14%
- H U M I R A7%
- Botox Therapeutic6%
- Vraylar6%
- Imbruvica5%
- Other34%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Skyrizi | $5.17B | $7.76B | $11.72B | $17.56B | 28.7% |
| Rinvoq | $2.52B | $3.97B | $5.97B | $8.3B | 13.6% |
| H U M I R A | $21.24B | $14.4B | $8.99B | $4.54B | 7.4% |
| Botox Therapeutic | $2.72B | $2.99B | $3.28B | $3.77B | 6.2% |
| Vraylar | $2.04B | $2.76B | $3.27B | $3.62B | 5.9% |
| Imbruvica | $4.57B | $3.6B | $3.35B | $2.87B | 4.7% |
| Other | $19.81B | $18.84B | $19.76B | $20.5B | 33.5% |
| Total revenue | $58.05B | $54.32B | $56.33B | $61.16B | 100% |
Revenue by region
Where AbbVie Inc. generates its revenue.
- United States76%
- Outside the US4%
- Other20%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| United States | $23.91B | $34.88B | $43.51B | $45.71B | $41.88B | $43.03B | $46.6B | 76.2% |
| Outside the US | $9.36B | $10.93B | $12.69B | $12.34B | $12.44B | $13.31B | $2.36B | 3.9% |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $12.19B | 19.9% |
| Total revenue | $33.27B | $45.8B | $56.2B | $58.05B | $54.32B | $56.33B | $61.16B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.